Kolorektal Kanserde İrinotekan Sitotoksisitesini Arttırmak için TGF-Β Sinyalizasyonunun Modülasyonu

Öz

Amaç: Bozulmuş  Transforme edici büyüme faktörü beta (Transforming Growth Factor Beta, TGF-β) sinyalizasyonu kolorektal kanser (CRC) ilerlemesine katkıda bulunur. TGF-β reseptörlerini (TGFβR) bilinen kemoterapilerle birlikte hedeflemek tedavi etkinliğini artırabilir. Amacımız insan kolorektal kanser hücre hattı HCT-116'da TGFβR-I/II inhibitörü (LY2109761) ile irinotekanın sitotoksik aktivitesine olan etkilerinin belirlenmesidir.

Materyal ve metod: HCT-116 hücrelerinde TGFβR-I/II'yi farmakolojik olarak inhibe etmek için LY2109761 inhibitörü kullanıldı. MTT analizleri, irinotekan, LY2109761 ve bunların kombinasyonu ile tedaviden sonraki hücre canlılığı değerlendirildi. Kantitatif Real Time PCR (RT-qPCR) ile, hücre ölümü, hücre döngüsü ve TGF-β sinyalizasyonu ile ilişkili genlerin mRNA düzeyleri değerlendirildi.

Bulgular: LY2109761 ve irinotekanın kombinasyon tedavisi, HCT-116 hücrelerinde hücre canlılığını doza ve zamana bağlı bir şekilde önemli ölçüde azalttı. Hücre döngüsü inhibitörü P21'in artan ekspresyonu ve apoptoz ve otofaji belirteçlerinin arttığı gözlemlendi.

Sonuç: LY2109761 ve irinotekanın kombinasyonu, irinotekanın tek başına kullanımına kıyasla artan sitotoksisite sonucu CRC için umut verici bir tedavi stratejisi olduğunu göstermektedir. Anahtar Kelimeler: Kolorektal kanser, TGFβR-I/II, İrinotekan, LY2109761, Sitotoksisite

Anahtar Kelimeler

• Kolorektal kanser
• TGFβR-I/II
• İrinotekan
• LY2109761
• Sitotoksisite

Proje Numarası

yok

Etik Beyan

This study does not involve any clinical or experimental research on humans or animals that would require ethical committee approval.

Modulation of TGF-Β Signaling to Enhance Irinotecan Cytotoxicity in Colorectal Cancer

Öz

Background: Impaired Transforming Growth Factor Beta (TGF-β) signaling contributes to colorectal cancer (CRC) progression. Targeting TGF-β receptors (TGFβR) in combination with established chemotherapies may enhance treatment efficacy. This study investigates the effects of a TGFβR-I/II inhibitor (LY2109761) on the cytotoxic activity of irinotecan in the human colorectal cancer cell line HCT-116.

Materials and Methods: LY2109761 was used to pharmacologically inhibit TGFβR-I/II in HCT-116 cells. Cell viability following treatment with irinotecan, LY2109761, or their combination was assessed using the MTT assay. Real-time quantitative polymerase chain reaction (RT-qPCR) quantified mRNA levels of genes associated with cell death, cell cycle, and TGF-β signaling.

Results: Combination therapy of LY2109761 and irinotecan significantly reduced cell viability in HCT-116 cells in a dose- and time-dependent manner. Enhanced expression of cell cycle inhibitor P21 and increased markers of apoptosis and autophagy were observed.

Conclusions:  The combination of LY2109761 and irinotecan exhibited enhanced cytotoxicity compared to irinotecan alone, suggesting this approach as a promising therapeutic strategy for CRC.

 

Anahtar Kelimeler

• Colorectal cancer
• TGFβR-I/II
• Irinotecan
• LY2109761
• Cytotoxicity

Proje Numarası

yok

Etik Beyan

This study does not involve any clinical or experimental research on humans or animals that would require ethical committee approval.

Kaynakça

1. 1. Gupta S. Screening for Colorectal Cancer. Hematol Oncol Clin North Am. 2022;36(3):393-414.
2. 2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
3. 3. Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal Cancer: Epidemiology, Risk Factors, and Prevention. Cancers (Basel). 2024;16(8):1530.
4. 4. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(7):627-47.
5. 5. International Agency for Research on Cancer. World Health Organisation [https://www.iarc.who.int/]. Data visualization tools for exploring the global cancer burden in 2022 Online Resources. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/792-turkiye-fact-sheet.pdf (https://gco.iarc.fr/en).
6. 6. Smith HG, Nilsson PJ, Shogan BD, Harji D, Gambacorta MA, Romano A, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8(3):zrae038.
7. 7. Jiao J, Wu Y, Wu S, Jiang J. Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy. Curr Treat Options Oncol. 2025;26(3):213-25.
8. 8. Shi J, Sun Z, Gao Z, Huang D, Hong H, Gu J. Radioimmunotherapy in colorectal cancer treatment: present and future. Front Immunol. 2023;14:1105180.

9. 9. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018 Oct;57(10):1229-54.
10. 10. Jiang W, Liu Q, Yang D, Yang SB. The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. Medicine (Baltimore). 2022;101(41):e28090.
11. 11. Paulík A, Nekvindová J, Filip S. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori. 2020;106(2):87-94.
12. 12. Kok SY, Nakayama M, Morita A, Oshima H, Oshima M. Genetic and nongenetic mechanisms for colorectal cancer evolution. Cancer Sci. 2023;114(9):3478-86.
13. 13. Yan H, Jiang F, Yang J. Association of β-Catenin, APC, SMAD3/4, Tp53, and Cyclin D1 Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis. Genet Res (Camb). 2022;2022:5338956.
14. 14. Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel). 2018;10(1):26.
15. 15. Derynck R, Budi EH. Specificity, versatility, and control of TGF-β family signaling. Sci Signal. 2019;12(570):eaav5183.
16. 16. Li X, Wu Y, Tian T. TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development. Int J Mol Sci. 2022;23(22):14436.
17. 17. Feng Y, Pauklin S. Two Sides of the Same Coin: The Roles of Transforming Growth Factor-β in Colorectal Carcinogenesis. Gastroenterology. 2020;159(1):397-98.
18. 18. Shan H, Tian G, Zhang Y, Qiu Z. Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer. Cancer Biol Ther. 2024;25(1):2392341.
19. 19. Zhang BH, Wang C, Dong W, Chen X, Leng C, Luo X, et al. A novel approach for monitoring TGF-β signaling in vivo in colon cancer. Carcinogenesis. 2021;42(4):631-9.
20. 20. Zhou J, Jiang W, Huang W, Ye M, Zhu X. Prognostic Values of Transforming Growth Factor-Beta Subtypes in Ovarian Cancer. Biomed Res Int. 2020;2020:2170606.
21. 21. Wang J, Xiang H, Lu Y, Wu T. Role and clinical significance of TGF β1 and TGF βR1 in malignant tumors (Review). Int J Mol Med. 2021;47(4):55.
22. 22. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, et al.Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011;71(23):7155-67.
23. 23. Gao Y, Shan N, Zhao C, Wang Y, Xu F, Li J et al.LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells. Int J Clin Exp Pathol. 2015;8(5):4923-32.
24. 24. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int J Mol Sci. 2021;22(23):12827.
25. 25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
26. 26. Colak S, Ten Dijke P. Targeting TGF-β Signaling in Cancer. Trends Cancer. 2017;3(1):56-71.
27. 27. White RA, Malkoski SP, Wang XJ. TGFβ signaling in head and neck squamous cell carcinoma. Oncogene. 2010;29(40):5437-46.
28. 28. Papageorgis P. TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol. 2015;2015:587193.
29. 29. Xue VW, Chung JY, Córdoba CAG, Cheung AH, Kang W, Lam EW, et al.Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity. Cancers (Basel). 2020;12(11):3099.
30. 30. Donovan J, Slingerland J. Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Res. 2000;2(2):116-24.
31. 31. Baba AB, Rah B, Bhat GR, Mushtaq I, Parveen S, Hassan R, et al.Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within. Front Pharmacol. 2022;13:791272.
32. 32. Yoshida K, Matsuzaki K, Murata M, Yamaguchi T, Suwa K, Okazaki K. Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis. Cancers (Basel). 2018;10(6):183.
33. 33. Katz LH, Li Y, Chen JS, Muñoz NM, Majumdar A, Chen J, et al. Targeting TGF-β signaling in cancer. Expert Opin Ther Targets. 2013;17(7):743-60.
34. 34. Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol. 2021;14(1):55.
35. 35. Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Ann Oncol. 2020;31(10):1336-1349.
36. 36. Huynh LK, Hipolito CJ, Ten Dijke P. A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment. Biomolecules. 2019;9(11):743.
37. 37. Paulík A, Nekvindová J, Filip S. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori. 2020;106(2):87-94.